Teva launches authorized generic version of Pfizer's Detrol LA

Drug had sales of $571.5 million in 12-month period ended Sept. 30

JERUSALEM — Teva Pharmaceutical Industries has launched an authorized generic version of a drug used to treat overactive bladder, the company said Friday.

Teva announced the launch of authorized generic tolterodine tartrate extended-release capsules in the 2-mg and 4-mg strengths. Authorized generics are branded drugs marketed under their generic names at a discounted price, usually under contracts between the branded manufacturers and third-party companies.

The drug is a version of Pfizer's Detrol LA, which had sales of about $571.5 million during the 12-month period that ended in September, according to IMS Health.


Login or Register to post a comment.